Clinical Trial DataUpdated P2 data of palazestrant plus ribociclib in ER+/HER2- advanced/metastatic breast cancer shows a promising clinical benefit rate of 85% across 13 evaluable patients.
Financial PerformanceThe company ended the quarter with a strong financial position, boasting $239.1 million in cash reserves.
Safety And EfficacyNo new safety signals were seen, nor any meaningful impact on drug exposure of either therapy was observed, highlighting the combination's strong safety profile.